Maintaining Bone Health During Hormonal Therapy for Prostate Cancer
Authors: Azeez Farooki, Howard I. Scher
Journal: Annals of Internal Medicine (2017)

Editorials5 September 2017Maintaining Bone Health During Hormonal Therapy for Prostate CancerAzeez Farooki, MD and Howard I. Scher, MDAzeez Farooki, MDFrom Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.Search for more papers by this author and Howard I. Scher, MDFrom Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M17-1800 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The prostate cancer disease continuum can be divided into states categorized by the status of the primary tumor (treated or untreated), the presence or absence of metastatic disease, and the serum level of testosterone. Each state includes patients with a range of prognoses, some of whom require immediate treatment. The competing risks from disease manifestations currently present or anticipated in the near term relative to comorbidities and life expectancy guide treatment decisions. For patients with metastatic disease or earlier-state aggressive tumors (for example, high-risk localized tumors) that are predicted to cause morbidity or shorten life expectancy, androgen deprivation therapy (ADT) ...References1. Alibhai SMH, Zukotynski K, Walker-Dilks C, Emmenegger U, Finelli A, Morgan SC, et al. Bone health and bone-targeted therapies for nonmetastatic prostate cancer. A systematic review and meta-analysis. Ann Intern Med. 2017;167:341-50. doi:10.7326/M16-2577 LinkGoogle Scholar2. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23:7897-903. [PMID: 16258089] CrossrefMedlineGoogle Scholar3. Qaseem A, Forciea MA, McLean RM, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166:818-839. [PMID: 28492856]. doi:10.7326/M15-1361 LinkGoogle Scholar4. Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007;25:1038-42. [PMID: 17369566] CrossrefMedlineGoogle Scholar5. Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B. Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab. 2017;102:354-358. [PMID: 27732330] doi:10.1210/jc.2016-3170 CrossrefMedlineGoogle Scholar6. Greenspan SL, Wagner J, Nelson JB, Perera S, Britton C, Resnick NM. Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy. J Bone Miner Res. 2013;28:325-32. [PMID: 22991066] doi:10.1002/jbmr.1771 CrossrefMedlineGoogle Scholar7. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, et al; Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745-55. [PMID: 19671656] doi:10.1056/NEJMoa0809003 CrossrefMedlineGoogle Scholar8. Cianferotti L, Bertoldo F, Carini M, Kanis JA, Lapini A, Longo N, et al. The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the International Osteoporosis Foundation. Oncotarget. 2017. [PMID: 28598810] doi:10.18632/oncotarget.17980 CrossrefMedlineGoogle Scholar9. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al; LATITUDE Investigators.. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017. [PMID: 28578607] doi:10.1056/NEJMoa1704174 CrossrefMedlineGoogle Scholar10. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al; STAMPEDE Investigators. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017. [PMID: 28578639] doi:10.1056/NEJMoa1702900 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-1800.Corresponding Author: Howard I. Scher, MD, Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Sidney Kimmel Center for Prostate and Urologic Cancers, 1275 York Avenue, New York, NY 10021; e-mail, [email protected]org.Current Author Addresses: Dr. Farooki: Endocrinology Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 296, New York, NY 10065.Dr. Scher: Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Sidney Kimmel Center for Prostate and Urologic Cancers, 1275 York Avenue, New York, NY 10021.This article was published at Annals.org on 8 August 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoBone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer Shabbir M.H. Alibhai , Katherine Zukotynski , Cindy Walker-Dilks , Urban Emmenegger , Antonio Finelli , Scott C. Morgan , Sebastién J. Hotte , George A. Tomlinson , and Eric Winquist Metrics Cited byRadium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study 5 September 2017Volume 167, Issue 5Page: 357-358KeywordsBoneBone mineral densityEstrogensLife expectancyOsteoporosisProstate cancerProstate diseasesSpineSystematic reviewsTestosterone ePublished: 8 August 2017 Issue Published: 5 September 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...